Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

This study tests a new experimental drug called ISM8207 in patients with advanced solid tumors or relapsed/refractory B-cell lymphoma (a cancer of the immune system's B cells). ISM8207 works by blocking a "don't eat me" signal that cancer cells use to hide from the immune system. **You may be eligible if...** - You are 18 or older with a confirmed advanced or metastatic solid tumor, or B-cell lymphoma that has returned or stopped responding to standard treatment - You have measurable cancer on scans - You are in good general health (ECOG 0–1) with a life expectancy of at least 12 weeks - Your organ function meets the study requirements **You may NOT be eligible if...** - You have previously received treatment with QPCTL, CD47, or SIRPα inhibitors - You have Burkitt lymphoma, plasma cell myeloma, or plasmablastic lymphoma - You have had cancer treatment within 28 days or 5 half-lives before the first dose - You have serious unresolved side effects from prior treatment - You have had a stem cell transplant within 3 months Talk to your doctor to see if this trial is right for you.